Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: A cost-effectiveness analysis in the era of biosimilar

Clinical and Experimental Rheumatology

Volumn 33, Issue 1, 2015, Pages 20-26

  Wu, Bin ^a   Song, Yang ^a   Leng, Lin ^b   Bucala, Richard ^b   Lu, Liang Jing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness analysis; Disease modifying anti rheumatic drugs; Etanercept biosimilar; Health related quality of life; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; YISAIPU; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CHINA; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL FEE; MIDDLE AGED; PRIORITY JOURNAL; PROCESS MODEL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; BIOASSAY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG ADMINISTRATION; DRUG COST; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; SUPPLY AND DISTRIBUTION; TIME; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; CHINA; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; ENDPOINT DETERMINATION; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOGLOBULIN G; MODELS, ECONOMIC; PATIENT SELECTION; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928697819     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. DAI SM, HAN XH, ZHAO DB, SHI YQ, LIU Y, MENG JM: Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol 2003; 30: 2245-51.
2. ZENG QY, CHEN R, DARMAWAN J et al.: Rheumatic diseases in China. Arthritis Res Ther 2008; 10: R17.
3. SCHOELS M, WONG J, SCOTT DL et al.: Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 995-1003.
4. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
5. SMOLEN JS, ALETAHA D, KOELLER M, WEISMAN MH, EMERY P: New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
6. KLARESKOG L, CATRINA AI, PAGET S: Rheumatoid arthritis. Lancet 2009; 373: 659-72.
7. SMOLEN JS, NASH P, DUREZ P et al.: Main-tenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013; 381: 918-29.
8. MIOSSEC P: Rheumatoid arthritis: still a chronic disease. Lancet 2013; 381: 884-6.
9. DORNER T, STRAND V, CASTANEDA-HERNANDEZ G et al.: The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72: 322-8.
10. SCHEINBERG MA, KAY J: The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012; 8: 430-6.
11. HU D, BAO C, CHEN S et al.: A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. Rheumatol Int 2009; 29: 297-303.
12. WU QJ, ZHANG ZL, LI ZB et al.: An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor-alpha receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and radiographic results from ReABLE study. Zhonghua Yi Xue Za Zhi 2010; 90: 2481-5.
13. KARNON J, STAHL J, BRENNAN A et al.: Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Value Health 2012; 15: 821-7.
14. BERESNIAK A, DUPONT DM, BECKER JC, MERKESDAL S: Interest of modelling in rheumatoid arthritis. Clin Exp Rheumatol 2012; 30: S96-101.
15. LU LJ, BAO CD, DAI M et al.: Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 2009; 61: 979-87.
16. HETLAND ML, CHRISTENSEN IJ, TARP U et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
17. WU B, WILSON A, WANG FF et al.: Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One 2012; 7: e47373.
18. Life tables for WHO Member States. http://www.who.int/healthinfo/statistics/mortality_life_tables/en/. Accessed 2012 September 18.
19. BARTON P, JOBANPUTRA P, WILSON J, BRYAN S, BURLS A: The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis-Introduction. Health Technol Assess 2004; 8: 1-91.
20. OLLENDORF DA, KLINGMAN D, HAZARD E, RAY S: Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009; 31: 825-35.
21. SOINI EJ, HALLINEN TA, PUOLAKKA K, VIHERVAARA V, KAUPPI MJ: Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012; 15: 340-51.
22. KOBELT G, EBERHARDT K, JONSSON L, JONSSON B: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347-56.
23. YELIN E, WANKE LA: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209-18.
24. KEYSTONE EC, COHEN SB, EMERY P et al.: Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012; 39: 2238-46.
25. BRENNAN A, BANSBACK N, REYNOLDS A, CONWAY P: Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004; 43: 62-72.
26. GORDON P, WEST J, JONES H, GIBSON T: A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001; 28: 2409-15.
27. List of Chinese administrative divisions by GDP per capita. http://en.wikipedia.org/wiki/List_of_Chinese_administrative_divisions_by_GDP_per_capita. Accessed October 28, 2011.
28. EICHLER HG, KONG SX, GERTH WC, MAVROS P, JöNSSON B: Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004; 7: 518-28.
29. MURRAY CJ, EVANS DB, ACHARYA A, BALTUSSEN RM: Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000; 9: 235-51.
30. ZHAO FL, YUE M, YANG H, WANG T, WU JH, LI SC: Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care 2011; 49: 267-72.
31. SCHOELS M, WONG J, SCOTT DL et al.: Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 995-1003.
32. KOBELT G, LEKANDER I, LANG A, RAFFEINER B, BOTSIOS C, GEBOREK P: Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011; 27: 193-200.
33. van den HOUT WB: Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA. Nat Clin Pract Rheumatol 2009; 5: 78-9.
34. CHEN XX, DAI Q, HUANG AB et al.: A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis. Clin Rheumatol 2013; 32: 99-108.
35. BERESNIAK A, BAERWALD C, ZEIDLER H et al.: Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clin Exp Rheumatol 2013; 31: 400-8.